Associate Director, Translational Medicine, Genomics Early R&D Oncology AstraZeneca
The prevailing position is that on-market Homologous Recombination (HR) DNA repair assays are sufficient to predict PARPi response in breast and ovarian cancer patients. While these assays detect the presence of genomic scars that that correlate with HRD, platinum and PARPi sensitivity, they miss subsequent events such as HRR gene promoter demethylation that restore HR proficiency and confer acquired platinum and PARPi resistance. In this workshop we will review data leveraging Pillar Biosciences rapid oncoRevealTM 4-Gene Methylation Panel (BRCA1, BRCA2, RAD51C, XRCC3) to inform methylation status as a potential additional biomarker to BRCAm and HRD scoring to guide the use of PARPi in advanced breast and other cancers.
